glp 1 blood clots Do GLP-1 Drugs Cause Clots? Evidence and Guidance GLP-1 Drugs Cut Death, Blood

So, if weve got a population thats already at high risk for a lot of these things and then theyre getting slammed on too high doses of this peptide, we have a problem

The decision to use tirzepatide in MS patients should be based on: Presence of appropriate indications (type 2 diabetes or obesity with BMI 30 kg/m or 27 kg/m with weight-related comorbidity) Absence of contraindications Patient-specific factors including MS disease activity, functional status, and treatment goals Coordination between neurology and primary care/endocrinology teams Future research priorities should include prospective observational studies examining metabolic medication safety and efficacy in MS cohorts, as well as exploratory studies investigating whether weight loss and metabolic optimization influence MS disease trajectories

doi.org/10.1111/dom.15728 4 Tinsley GM, Nadolsky S

In those opening weeks, she said you might feel mild nausea that usually eases over time, notice you're less hungry and full sooner, and start to see some early weight loss

The fat-to-lean mass ratio improved from 0.93 at baseline to 0.70 at week 72 in the tirzepatide group, compared to 0.95 to 0.88 in the placebo group

Writing original draft: GMT